Effect of Osimertinib in Non-Small Cell Lung Cancer Patients with Brain Metastases After Progression Following Front-Line EGFR-TKI Therapy

被引：1
|
作者：
Yu, X. [1 ]
Fan, Y. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Osimertinib; Brain metastases; epidermal growth factor receptor tyrosine kinase inhibitor;
D O I：
10.1016/j.jtho.2019.08.815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-100
引用
收藏
页码：S400 / S400
页数：1
相关论文
共 50 条
  • [21] Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Kogure, Yoshihito
    Saka, Hideo
    Oki, Masahide
    Saito, Toshiki I.
    Ahmed, Shimaa Nour Moursi
    Kitagawa, Chiyoe
    Imaizumi, Kazuyoshi
    PLOS ONE, 2015, 10 (08):
  • [22] REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Yamauchi, Hiroyoshi
    Nakayama, Masayuki
    Yamamoto, Shinichi
    Saito, Tatsuya
    Okuyama, Akiko
    Mato, Naoko
    Yamasawa, Hideaki
    Suzuki, Takuji
    Bando, Masashi
    Hagiwara, Koichi
    RESPIROLOGY, 2017, 22 : 242 - 242
  • [23] Radium-223 following front-line chemotherapy for patients with non-small cell lung cancer and bone metastases
    Taber, Angela Marie
    Riley, David
    Olszewski, Adam J.
    Birnbaum, Ariel E.
    Khurshid, Humera
    Yoo, Don
    Noto, Richard
    Rosati, Kayla
    Safran, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
    Fan, Yun
    Xu, Xiaoling
    Xie, Conghua
    ONCOTARGETS AND THERAPY, 2014, 7 : 2075 - 2084
  • [25] Efficacy of EGFR-TKI therapy in patients with brain metastases from non-small-cell lung cancer: A meta-analysis
    Zhang, Wei
    Hu, Lijuan
    Huang, Caihong
    Ying, Jun
    Zhao, Naiqing
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2017, 16 (11) : 2761 - 2772
  • [26] Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI
    Yang, Beisheng
    Luo, Chunli
    Yu, Min
    Zhou, Lin
    Tao, Bo
    Tang, Biqiu
    Zhou, Ying
    Zhu, Jiang
    Huang, Meijuan
    Peng, Feng
    Liu, Yongmei
    Xu, Yong
    Zhang, Yan
    Zhou, Xiaojuan
    Xue, Jianxin
    Li, Yanying
    Wang, Yongsheng
    Li, Zhiping
    Lu, You
    Lui, Su
    Gong, Youling
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [27] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185)
    Li, Xin
    Liu, Minghui
    Zhang, Hongbing
    Liu, Hongyu
    Chen, Jun
    THORACIC CANCER, 2020, 11 (03) : 819 - 826
  • [29] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [30] EGFR-TKI AFTER DISEASE PROGRESSION WITH CENTRAL NERVOUS SYSTEM METASTASIS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS
    Kasahara, Kazuo
    Sone, Takashi
    Shibata, Kazuhiko
    Shirasaki, Hiroki
    Kita, Toshiyuki
    Sakai, Asao
    Nishikawa, Shingo
    Yoneda, Taro
    Kimura, Hideharu
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1210 - S1210
12345